This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Investors -2- DJ
Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from NASDAQ Composite Index CI
Science 37 Holdings, Inc.(NasdaqCM:SNCE) dropped from S&P TMI Index CI
North American Morning Briefing : Stock Futures -2- DJ
EMed, LLC completed the acquisition of Science 37 Holdings, Inc.. CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Big Tech Weighs -2- DJ
Baird Downgrades Science 37 Holdings to Neutral From Outperform, Price Target is $5.75 MT
North American Morning Briefing : Microsoft Kicks -2- DJ
Baird Adjusts Science 37 Holdings' Price Target to $5.75 From $15, Keeps Outperform Rating MT
Craig-Hallum Downgrades Science 37 Holdings to Hold From Buy MT
Science 37 to be Acquired by eMed for About $38 Million in Cash MT
EMed, LLC entered into a definitive merger agreement to acquire Science 37 Holdings, Inc.. CI
Science 37 Holdings, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Transcript : Science 37 Holdings, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (SNCE) SCIENCE 37 Posts Q3 Revenue $14.9M, vs. Street Est of $14.8M MT
Science 37 Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Science 37 Holdings, Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Science 37 Holdings, Inc. Reports Impairment for the Third Quarter Ended September 30, 2023 CI
Transcript : Science 37 Holdings, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Earnings Flash (SNCE) SCIENCE 37 Reports Q2 Revenue $15.4M, vs. Street Est of $12.6M MT
Science 37 Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Science 37 Holdings, Inc. Revises Revenue Guidance for the Full Year 2023 CI
Science 37 Holdings, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2023 CI
Science 37's Metasite Selected by Synlogic for Virtual Clinical-Trial Platform for Potential Phenylketonuria Treatment MT
Chart Science 37 Holdings, Inc.
More charts
Science 37 Holdings, Inc. is engaged in patient-centric clinical trials and in supporting novel approaches to decentralized clinical trial designs. Through its patient-centric approach, it reduces the impact of the geographic barriers associated with conventional physical clinical trial sites, enabling recruitment of virtually any patient. Its offerings lie in its configurable unified technology platform combined with its centralized patient recruitment capabilities and specialized network of patient communities. Its unified technology platform is purpose-built for patient-centric clinical trial execution and is designed to provide an end-to-end, single stop solution. It also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, and remote coordinators designed for the purpose of orchestrating patient-centric clinical trials. It uses diversified, multi-channel programs to identify patients who fit the profile for each of its projects.
More about the company
  1. Stock Market
  2. Equities
  3. SNCE Stock
  4. News Science 37 Holdings, Inc.
  5. Science 37's Metasite Selected by Synlogic for Virtual Clinical-Trial Platform for Potential Phenylketonuria Treatment